IQAIF / IQ-AI subsidiary wins orphan drug status for pediatric brain tumour treatment

IQ-AI has highlighted a new study into a rare form of brain cancer that used subsidiary Imaging  Biometric's dynamic susceptibility contrast (DSC) ma more_horizontal

IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF)'s subsidiary, Imaging Biometrics, has secured orphan drug designation from the US Food and Drug Administration for more_horizontal

Imaging Biometrics (IB), a subsidiary of IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF), has confirmed the effectiveness of its IB Neuro technology for brain scan more_horizontal

IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) said it aims to convert a significant portion of the 45 sites currently assessing its IB imaging software into clien more_horizontal

IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF)'s wholly owned subsidiary Imaging Biometrics has had its handheld application IB Nimble selected by the Orthopedic D more_horizontal

IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) surged in early-Thursday trades following a promising update from its subsidiary Imaging Biometrics. Imaging Biometr more_horizontal

Imaging Biometrics, a wholly-owned subsidiary of IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF), been has granted orphan drug designation (ODD) status for its oral more_horizontal

IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF), the company focused on delivering imaging platforms to treat patients more effectively, enjoyed a boost on the Lond more_horizontal